Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31075343 | 0.84 | — | — | |
| SCHEMBL31075606 | 0.76 | — | — | |
| SCHEMBL11437981 | 0.75 | KDM4E (0.48) | ANPEPERAP2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3585774 | 0.73 | KDM4E (0.50) | ANPEPERAP2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL9810147 | 0.73 | KDM4E (0.50) | ANPEPERAP2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL31390192 | 0.72 | — | — | |
| SCHEMBL28080703 | 0.71 | KDM4E (0.52) | ANPEPERAP2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL29100048 | 0.70 | KDM4E (0.50) | ANPEPERAP2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL30411672 | 0.69 | KDM4E (0.50) | ANPEPERAP2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL2801217 | 0.69 | KDM4E (0.54) | ANPEPERAP2KDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043094-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024177984-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |